Infliximab NEW
| Price | $98 | $162 | $273 |
| Package | 1mg | 2mg | 5mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-18 |
Product Details
| Product Name: Infliximab | CAS No.: 170277-31-3 |
| Purity: 99.70% | Supply Ability: 10g |
| Release date: 2024/11/18 |
Product Introduction
Bioactivity
| Name | Infliximab |
| Description | Infliximab is a monoclonal antibody, a human-mouse chimeric monoclonal antibody that inhibits TNF-α and prevents TNF-α from interacting with TNFR1 and TNFR2. Infliximab can be used to treat Crohn's disease and rheumatoid arthritis. |
| In vitro | METHODS: Human lung cancer cells A549 were pretreated with ML162 (0.1-15 μM) for 4-24 h. TXNRD1 activity was measured with the RX1 activity probe. RESULTS: RX1 signaling was significantly dose-dependently inhibited at ML162 concentrations of 0.5 μM or higher. there was also a fairly rapid onset of concentration-dependent inhibition of cellular TXNRD1 activity by ML162, and a 4 h incubation with 1 μM or higher ML162 treatment was sufficient to inhibit RX1 signaling. ML162 effectively inhibited cellular TXNRD1 activity.[1] METHODS: Melanoma cells A2058 and A375 were pretreated with ferrostatin (10 μM), Z-VAD-FMK (10 μM), or necrosulfonamide (0.5 μM) for 24 h, and cell viability was measured after ML162 (1-16 μM) treatment. RESULTS: ML162 caused cell death in a dose-dependent manner in the A2058 and A375 melanoma cell lines, which could be reversed by ferrostatin-1, a ferritin-specific inhibitor, but not by Z-VAD-FMK, an inhibitor of apoptosis, or necrosulfonamide, an inhibitor of necroptosis. [2] |
| In vivo | METHODS: To detect anti-tumor activity in vivo, ML162 (40 mg/kg once daily) and anti-PD-1 antibody (200 μg every three days) were intraperitoneally injected into BALB/c mice bearing TS/A tumors once daily for two weeks. RESULTS: The combination of GPX4 inhibitor and anti-PD-1 antibody significantly inhibited tumor growth compared to monotherapy. The combination therapy did not result in additional immune cell infiltration compared to monotherapy, but the combination therapy induced a significant immune response with an increased proportion of PRF1+CD8+ T cells and GZMB+CD8+ T cells. [3] |
| Storage | store at low temperature | store at -20°C | Shipping with blue ice. |
| Keywords | TNFR1 | anti-inflammatory | Avakine | Tumor Necrosis Factor Receptor | autoimmune | diabetic | Infliximab | TNFR | PTP1B | neuropathy | Inhibitor | TNFR2 | monoclonal | TNF Receptor | inhibit | CT-P13 |
| Inhibitors Related | Cepharanthine | Acetylcysteine | Acefylline | Glucosamine | Thalidomide | Taurochenodeoxycholic Acid | Apremilast | Pomalidomide | Bergenin | Lenalidomide | Fisetin | Linalool |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $0.00/1kg |
VIP4Y
|
Sinoway Industrial co., ltd.
|
2024-07-17 | |
| $1.10/1g |
VIP4Y
|
Dideu Industries Group Limited
|
2021-07-01 | |
| $0.00/1Kg |
VIP6Y
|
Shaanxi Dideu Medichem Co. Ltd
|
2020-04-30 |
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY